Home Stock

Stock Research: Santen Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Santen Pharmaceutical

TYO:4536 JP3336000009
89
  • Value
    46
  • Growth
    73
  • Safety
    Safety
    75
  • Combined
    81
  • Sentiment
    80
  • 360° View
    360° View
    89
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company focused on the research, development, manufacturing, and sales of pharmaceutical products. It operates in medical pharmaceutical, OTC drugs, medical devices, and other businesses, including the cleaning business. The company operates in Japan, Europe, Asia, and North America markets. In the last fiscal year, the company had 3849 employees, a market cap of $3814 million, profits of $1141 million, and revenue of $2001 million.

more

ANALYSIS: With an Obermatt 360° View of 89 (better than 89% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Santen Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Santen Pharmaceutical. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 73% of competitors in the same industry. The consolidated Safety Rank at 75 means that the company has a financing structure that is safer than 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 80, which means that professional investors are more optimistic about the stock than for 80% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 46, meaning that the share price of Santen Pharmaceutical is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 54% of alternative stocks in the same industry. ...read more

more
Strongest Rank Refinancing
Weakest Rank Pro Holdings
Country Japan
Industry Pharmaceuticals
Size Large
Website santen.com
Index
Santen Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 72 70 77
Growth
73 20 51 43
Safety
Safety
75 61 80 84
Sentiment
80 58 70 27
360° View
360° View
89 55 94 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
57 65 39 31
Opinions Change
50 59 82 50
Pro Holdings
n/a 40 100 37
Market Pulse
45 56 26 47
Sentiment
80 58 70 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 72 70 77
Growth
73 20 51 43
Safety Safety
75 61 80 84
Combined
81 50 90 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 63 62 59
Price vs. Earnings (P/E)
59 76 63 78
Price vs. Book (P/B)
39 45 56 67
Dividend Yield
75 72 76 88
Value
46 72 70 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
21 4 8 16
Profit Growth
53 58 94 96
Capital Growth
91 23 23 43
Stock Returns
84 46 79 37
Growth
73 20 51 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
83 54 63 74
Refinancing
20 44 63 61
Liquidity
88 64 76 84
Safety Safety
75 61 80 84

Similar Stocks

Discover high‑ranked alternatives to Santen Pharmaceutical and broaden your portfolio horizons.

Brother Industries

TYO:6448
Country: Japan
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Cosmo Energy Holdings

TYO:5021
Country: Japan
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

Shimadzu

TYO:7701
Country: Japan
Industry: Electronic Equipment
Size: X-Large
Full Stock Analysis

NSK

TYO:6471
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews